Korea Disease Control and Prevention Agency agrees to buy edible Pfizer COVID-19 pills

½Åż· ±âÀÚl½ÂÀÎ2022.01.28

Å©°Ô

ÀÛ°Ô

¸ÞÀÏ

Àμâ

½Å°í

   

Amid protest of self-owned businessmen against the government's extension of toughened social distancing, Korea Disease Control and Prevention Agency signed a deal with Pfizer for edible COVID-19 pills. The protestors are not satisfied with 5 million won ($4,154) compensation because that is not enough to cover their loss caused by limited business hours or closure. Instead, they urged the government 1) lifting the quarantine pass 2) lifting limited business hours and 3) revision of the Compensation Act. On December 22, large number of them gathered on Gwanghwamun Plaza and some of them shaved their heads in gesture of their resistance. Meanwhile, COVID-19 pills Paxlovid is to cross the Pacific Ocean to Korea during this month and detailed plans for affected people and distribution are being discussed. The Agency has signed a contract to buy Paxlovid that can accommodate around 604,000 people but is working to increase the number to 1 million and 4,000. <PowerKorea>

 

PowerKorea is an official partner of Herald Corporation and the magazine is distributed to the KOTRA business centers in the world. We publish latest news of Samsung, Hyundai and government affairs and endeavor to serve as a platform to engage with people around the world. 


½Åż· ±âÀÚ  tss79@naver.com
<ÀúÀÛ±ÇÀÚ © ¿ù°£ÆÄ¿öÄÚ¸®¾Æ, ¹«´Ü ÀüÀç ¹× Àç¹èÆ÷ ±ÝÁö>

½Åż· ±âÀÚÀÇ ´Ù¸¥±â»ç º¸±â
°¡Àå ¸¹ÀÌ º» ±â»ç
¿©¹é
¿©¹é
½Å¹®»ç¼Ò°³¤ý±â»çÁ¦º¸¤ý±¤°í¹®ÀǤýºÒÆí½Å°í¤ý°³ÀÎÁ¤º¸Ãë±Þ¹æħ¤ýû¼Ò³âº¸È£Á¤Ã¥¤ýÀ̸ÞÀϹ«´Ü¼öÁý°ÅºÎ
¢ß´º½º¾Ø¸Å°ÅÁø ÆÄ¿öÄÚ¸®¾Æ ´ëÇ¥ ¹éÁ¾¿ø  |   ¼­¿ïƯº°½Ã ±¤Áø±¸ Á߰ 162-3¹øÁö 2Ãþ  |  ´ëÇ¥ÀüÈ­ : 02-466-5085  |  Æѽº : 02-444-0454
´ëÇ¥¸ÞÀÏ/Á¦ÈÞ±¤°í¹®ÀÇ : bridgekorea@naver.com  |  °³ÀÎÁ¤º¸°ü¸®Ã¥ÀÓÀÚ : ¹éÁ¾¿ø(bridgekorea@naver.com)  |  »ç¾÷ÀÚµî·Ï¹øÈ£ : 591-87-01957
û¼Ò³âº¸È£Ã¥ÀÓÀÚ : ¹éÁ¾¿ø
Disclaimer: PowerKorea makes an article based on the information of products and/or services provided in paper and/or in interview by the company, the organization or the person that is solely responsible for the information.
Copyright © 2008 - 2024 ¿ù°£ÆÄ¿öÄÚ¸®¾Æ. All rights reserved.